OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press77510.17650/1818-8346-2009-0-3-40-56HEMATOLOGIC MALIGNANCIES: TREATMENT, SUPPORTIVE CAREГЕМОБЛАСТОЗЫ: ЛЕЧЕНИЕ, СОПРОВОДИТЕЛЬНАЯ ТЕРАПИЯChronic myeloid leukemia — before and after imatinib (part II)Хронический миелолейкоз – до и после применения иматиниба (часть II)LomaiaE. G.ЛомаиаЕ. Г.Russian Federation
ГУ Федеральный центр сердца, крови и эндокринологии им. В. А. Алмазова, Санкт-ПетербургФГУ Санкт-Петербургский государственный медицинский универсистет им. И. П. ПавловаФГУ Санкт-Петербургский государственный медицинский универсистет им. И. П. ПавловаГУ Федеральный центр сердца, крови и эндокринологии им. В. А. Алмазова, Санкт-Петербург270820093405627112022271120222009https://oncohematology.abvpress.ru/ongm/article/view/775
.
.
1. Bennett J.H. Case of hypertrophy of the spleen and liver in which death took place from suppuration of the blood. Edinburgh Med Surg J 1845;64:413.Bennett J.H. Case of hypertrophy of the spleen and liver in which death took place from suppuration of the blood. Edinburgh Med Surg J 1845;64:413.2. Craigie D. Case of disease of the spleen in which death took place in consequence of the presence of purulent matter in the blood. Edinburgh Med Surg J 1845;64:400.Craigie D. Case of disease of the spleen in which death took place in consequence of the presence of purulent matter in the blood. Edinburgh Med Surg J 1845;64:400.3. Nowell P.C., Hungerford D.A. A minute chromosome in human chronic granulocytic leukemia. Science 1960;132:1497—501.Nowell P.C., Hungerford D.A. A minute chromosome in human chronic granulocytic leukemia. Science 1960;132:1497—501.4. Lugo T.G. et al. Tyrosin kinase activity and transformation potency of bcr-abl oncogene products. Science 1990;247:1079—82.Lugo T.G. et al. Tyrosin kinase activity and transformation potency of bcr-abl oncogene products. Science 1990;247:1079—82.5. Daley G.Q. et al. Induction of chronic myelogenous leukemia in mice by the P210 bcr/abl gene of the Philadelphia chromosome. Science 1990;247:824—30.Daley G.Q. et al. Induction of chronic myelogenous leukemia in mice by the P210 bcr/abl gene of the Philadelphia chromosome. Science 1990;247:824—30.6. Deininger M.W. et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997;90:3691—8.Deininger M.W. et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997;90:3691—8.7. Sawyers C.L. Tyrosine kinase inhibitors in chronic myeloid leukemia. Cancer J Sci Am 1999;5:63—9.Sawyers C.L. Tyrosine kinase inhibitors in chronic myeloid leukemia. Cancer J Sci Am 1999;5:63—9.8. Druker B.J. et al. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000;105:3—7.Druker B.J. et al. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000;105:3—7.9. Cowan-Jacob S. et al. Structural biology contributions to the discovery of drugs to treat of chronic myelogenous leukemia. Acta Cristallographica 2007;63;80—93.Cowan-Jacob S. et al. Structural biology contributions to the discovery of drugs to treat of chronic myelogenous leukemia. Acta Cristallographica 2007;63;80—93.10. Druker B.J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561—6.Druker B.J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561—6.11. Vigneri P., Wang J.Y. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 2001;7:228—34.Vigneri P., Wang J.Y. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 2001;7:228—34.12. Geay J.F., Buet D., Zhang Y. et al. p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression. Cancer Res 2005;65(7): 2676—83.Geay J.F., Buet D., Zhang Y. et al. p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression. Cancer Res 2005;65(7): 2676—83.13. Barnes K., McIntosh E., Whetton A.D. et al. Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation. Oncogene 2005;24(20):3257—67.Barnes K., McIntosh E., Whetton A.D. et al. Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation. Oncogene 2005;24(20):3257—67.14. Cullinane C., Dorow D.S., Kansara M. et al. An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development. Cancer Res 2005;65(21):9633—6.Cullinane C., Dorow D.S., Kansara M. et al. An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development. Cancer Res 2005;65(21):9633—6.15. Gambacorti-Passerini C., le Coutre P., Mologni L. et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 1997;23:380—94.Gambacorti-Passerini C., le Coutre P., Mologni L. et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 1997;23:380—94.16. Le Coutre P., Mologni L., Cleris L. In vivo eradication of human BCR/ABLpositive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 1991;91:163—8.Le Coutre P., Mologni L., Cleris L. In vivo eradication of human BCR/ABLpositive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 1991;91:163—8.17. Holyoake D.T. Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory. Br J Haematol 2001;113:11—23.Holyoake D.T. Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory. Br J Haematol 2001;113:11—23.18. Heinrich M.C. et al. Inhibition of c-KIT receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000;96:925—32.Heinrich M.C. et al. Inhibition of c-KIT receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000;96:925—32.19. Dewar A.L. et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 2005;105(8):3127—32.Dewar A.L. et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 2005;105(8):3127—32.20. Buchdunger E. et al. Abl proteintyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-KIT and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139—45.Buchdunger E. et al. Abl proteintyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-KIT and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139—45.21. Okuda K. et al. ARG tyrosine kinase activity is inhibited by STI571. Blood 2001;97(8):244.Okuda K. et al. ARG tyrosine kinase activity is inhibited by STI571. Blood 2001;97(8):244.22. Breccia M., Stefanizzi C., Cannella L. et al. Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia. Leuk Lymphoma 2008;49(12):2328—32.Breccia M., Stefanizzi C., Cannella L. et al. Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia. Leuk Lymphoma 2008;49(12):2328—32.23. Biswas S.K., Zhao Y., Sandirasegarane L. Imatinib induces apoptosis by inhibiting PDGF- but not insulin-induced PI 3-kinase. Akt survival signaling in RGC-5 retinal ganglion cells. Mol Vis 2009;15:1599—610.Biswas S.K., Zhao Y., Sandirasegarane L. Imatinib induces apoptosis by inhibiting PDGF- but not insulin-induced PI 3-kinase. Akt survival signaling in RGC-5 retinal ganglion cells. Mol Vis 2009;15:1599—610.24. Bueso-Ramos C.E. et al. Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia. Cancer 2004;101(2): 332—6.Bueso-Ramos C.E. et al. Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia. Cancer 2004;101(2): 332—6.25. Agis H., Jaeger E., Doninger B. et al. In vivo effects of imatinib mesylate on human haematopoietic progenitor cells. Eur J Clin Invest 2006;36:402—8.Agis H., Jaeger E., Doninger B. et al. In vivo effects of imatinib mesylate on human haematopoietic progenitor cells. Eur J Clin Invest 2006;36:402—8.26. Thiele J., Kvasnicka H.M., Schmitt-Graeff A. et al. Bone marrow changes in chronic myelogenous leukaemia after long-term treatment with the tyrosine kinase inhibitor STI571: an immunohistochemical study on 75 patients. Histopathology 2005;46(5): 540—50.Thiele J., Kvasnicka H.M., Schmitt-Graeff A. et al. Bone marrow changes in chronic myelogenous leukaemia after long-term treatment with the tyrosine kinase inhibitor STI571: an immunohistochemical study on 75 patients. Histopathology 2005;46(5): 540—50.27. Kvasnicka H.M., Thiele J., Staib P.et al. Therapy-related changes of angiogenesis in Philadelphia chromosome positive chronic myelogenous leukemia.Pathologe 2004;25(2):127—34.Kvasnicka H.M., Thiele J., Staib P.et al. Therapy-related changes of angiogenesis in Philadelphia chromosome positive chronic myelogenous leukemia.Pathologe 2004;25(2):127—34.28. Weisberg E. et al. Characterization of AMN107, a selective inhibitor of native and mutant BCR-ABL. Cancer Cell 2005;7(2):129—41.Weisberg E. et al. Characterization of AMN107, a selective inhibitor of native and mutant BCR-ABL. Cancer Cell 2005;7(2):129—41.29. Liu Y. et al. Rational design of inhibitors hat bind to inactive kinase conformations. Nat Chem Biol 2006;2(7):358—64.Liu Y. et al. Rational design of inhibitors hat bind to inactive kinase conformations. Nat Chem Biol 2006;2(7):358—64.30. O'Hare T. et al. In vitro activity of BCR-ABL inhibitors AMN-107 and BMS-354825 against clinically relevant imatinib-resistant ABL kinase domain mutants. Cancer Res 2005;65(11): 4500—5.O'Hare T. et al. In vitro activity of BCR-ABL inhibitors AMN-107 and BMS-354825 against clinically relevant imatinib-resistant ABL kinase domain mutants. Cancer Res 2005;65(11): 4500—5.31. Stover E.H. et al. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRβ and FIP1L1-PDGFRα in vitro and in vivo. Blood 2005;106(9):3206—13.Stover E.H. et al. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRβ and FIP1L1-PDGFRα in vitro and in vivo. Blood 2005;106(9):3206—13.32. Bubnoff von N. et al. The systemic mastocytosis -specific activating c-KIT mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107. Leukemia 2005; Advance online publication 1—2.Bubnoff von N. et al. The systemic mastocytosis -specific activating c-KIT mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107. Leukemia 2005; Advance online publication 1—2.33. Weisberg E. et al. AMN 107(nilotinib): a novel and selective inhibitor of bcr-abl. Br J Cancer 2006;94:1130—340.Weisberg E. et al. AMN 107(nilotinib): a novel and selective inhibitor of bcr-abl. Br J Cancer 2006;94:1130—340.34. Tokarski J.S. et al. The structure of Dasatinib (BMS354825) bound to activated abl kinase of domain elucidates its inhibitory activity against imatinib-resistant mutants. Cancer Res 2006;66: 5790—7.Tokarski J.S. et al. The structure of Dasatinib (BMS354825) bound to activated abl kinase of domain elucidates its inhibitory activity against imatinib-resistant mutants. Cancer Res 2006;66: 5790—7.35. O’Hare T. et al. In vitro activiy of AMN 107 and BMS354825 against clinically relevant imatinib-resistant abl kinase domain mutants. Cancer Res 2005; 65: 4500—5.O’Hare T. et al. In vitro activiy of AMN 107 and BMS354825 against clinically relevant imatinib-resistant abl kinase domain mutants. Cancer Res 2005; 65: 4500—5.36. Klejman A. et al. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid cells. EMBO J 2002;21:5766—74.Klejman A. et al. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid cells. EMBO J 2002;21:5766—74.37. Skorski T. et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI3-K/Akt dependent pathway. EMBO J 1997;16:6151—61.Skorski T. et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI3-K/Akt dependent pathway. EMBO J 1997;16:6151—61.38. Donato N.J. et al. BCR-ABL independence and Lyn kinase overexpression in chronic myeloid leukemia cells selected for resistance to STI571. Blood 2003;101:690—8.Donato N.J. et al. BCR-ABL independence and Lyn kinase overexpression in chronic myeloid leukemia cells selected for resistance to STI571. Blood 2003;101:690—8.39. Ptasznik A. et al. Short interfering RNA targeting the Lyn kinase indusec apoptosis in primary and drug-resistance BCR-ABL+ cells. Nat Med 2004;10:1187—98.Ptasznik A. et al. Short interfering RNA targeting the Lyn kinase indusec apoptosis in primary and drug-resistance BCR-ABL+ cells. Nat Med 2004;10:1187—98.40. Rix U. et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib reveal novel kinase and non-kinase targets. Blood 2007;First edition paper: 1—34.Rix U. et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib reveal novel kinase and non-kinase targets. Blood 2007;First edition paper: 1—34.41. Fabarius A. et al. Centrosome aberrations, disturbed mitotic spindle formation and G1 arrest in normal and leukemia cells treated with SRC/ABL inhibitor Dasatinib. Blood 206;108:614—5(a).Fabarius A. et al. Centrosome aberrations, disturbed mitotic spindle formation and G1 arrest in normal and leukemia cells treated with SRC/ABL inhibitor Dasatinib. Blood 206;108:614—5(a).42. Larson R. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008;111(8):4022—8.Larson R. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008;111(8):4022—8.43. Izzo A.A., Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 2009;69(13):1777—98.Izzo A.A., Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 2009;69(13):1777—98.44. Wang Y., Zhou L., Dutreix C. at al. Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia. Br J Clin Pharmacol 2008;65(6):885—92.Wang Y., Zhou L., Dutreix C. at al. Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia. Br J Clin Pharmacol 2008;65(6):885—92.45. Orhanos G.S., Joannidis G.N. Cardiotoxicity induced by tyrosine kinase inhibitors. Dep Oncol Acta Oncol 2009;4:1—7.Orhanos G.S., Joannidis G.N. Cardiotoxicity induced by tyrosine kinase inhibitors. Dep Oncol Acta Oncol 2009;4:1—7.46. Ridruejo E., Caccione R. et al. Imatinib-induced fatal acute liver failure. World J Gastroenterol 2007;13(48): 6608—11.Ridruejo E., Caccione R. et al. Imatinib-induced fatal acute liver failure. World J Gastroenterol 2007;13(48): 6608—11.47. Nikolova Z. et al. Bioequivalence, safety and tolerability of imatinib tablets compared with capsules. Cancer Chemother Pharmacol 2004;53:433—8.Nikolova Z. et al. Bioequivalence, safety and tolerability of imatinib tablets compared with capsules. Cancer Chemother Pharmacol 2004;53:433—8.48. Deremer D.L., Ustun C., Natarajan K. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther 2008;30(11):1956—75.Deremer D.L., Ustun C., Natarajan K. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther 2008;30(11):1956—75.49. Kagan M. et al. Safety, pharmacokinetics, metabolism and mass balance of AMN 107, a noval aminopyridine tirosin kinase inhibitor in healthy subjects. Blood 2005;106:302 (abstr 4887).Kagan M. et al. Safety, pharmacokinetics, metabolism and mass balance of AMN 107, a noval aminopyridine tirosin kinase inhibitor in healthy subjects. Blood 2005;106:302 (abstr 4887).50. Tanaka C. et al. Clinical pharmacokinetics of AMN107, a novel inhibitor of abl, in healthy subjects and patients with imatinib resistant and intolerant chronic myelogenous leukemia or relapsed/refractory Ph+-acute lymphoblastic leukemia. J Clin Oncol 2006;18(suppl 24):144 (abstr 3095).Tanaka C. et al. Clinical pharmacokinetics of AMN107, a novel inhibitor of abl, in healthy subjects and patients with imatinib resistant and intolerant chronic myelogenous leukemia or relapsed/refractory Ph+-acute lymphoblastic leukemia. J Clin Oncol 2006;18(suppl 24):144 (abstr 3095).51. Novartis pharmaceuticals corporation: East Hanover (NJ). TasignaR (Nilotinib capsules): US prescribing information [Online]. Available from URL: http://www.fda.govNovartis pharmaceuticals corporation: East Hanover (NJ). TasignaR (Nilotinib capsules): US prescribing information [Online]. Available from URL: http://www.fda.gov52. Singer J.B. et al. UGT1A1 promotor polymorphism increases risk of nilotinibinduced hyperbilirubinemia. Leukemia 2007;21:2311—5.Singer J.B. et al. UGT1A1 promotor polymorphism increases risk of nilotinibinduced hyperbilirubinemia. Leukemia 2007;21:2311—5.53. Hazarika M. et al. Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or in tolerant of Imatinib. Clin Cancer Res 2008;14(17):5325—31.Hazarika M. et al. Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or in tolerant of Imatinib. Clin Cancer Res 2008;14(17):5325—31.54. White D.L. et al. OCT-1 mediated influx is a key determinant of the intercellular uptake of imatinib but not nilotinib: OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006;108(2):697—704.White D.L. et al. OCT-1 mediated influx is a key determinant of the intercellular uptake of imatinib but not nilotinib: OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006;108(2):697—704.55. Brendel C. et al. Imatinibe mesilate and Nilotinib exhibit high-affinity interaction with ABCG2 on primitive hematopoetic stem cells. Leukemia 2007;109(8):3609—10.Brendel C. et al. Imatinibe mesilate and Nilotinib exhibit high-affinity interaction with ABCG2 on primitive hematopoetic stem cells. Leukemia 2007;109(8):3609—10.56. Davies A. et al. Characterization of nilotinib transport in chronic myeloid leukemia cells. Blood 2007;110:2364 (abstr).Davies A. et al. Characterization of nilotinib transport in chronic myeloid leukemia cells. Blood 2007;110:2364 (abstr).57. Tyler T. Once-daily dasatinib for treatment of patients with chronic myeloid leukemia. Ann Pharmacother 2009;43(5):920—7.Tyler T. Once-daily dasatinib for treatment of patients with chronic myeloid leukemia. Ann Pharmacother 2009;43(5):920—7.58. SprycelR prescribing information. Bristol Myers Squibb. NY, USA. 2007.SprycelR prescribing information. Bristol Myers Squibb. NY, USA. 2007.59. Giannoudis A., Davies A., Lucas C.M. et al. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood 2008;112(8):3348—54.Giannoudis A., Davies A., Lucas C.M. et al. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood 2008;112(8):3348—54.60. Egorin M.J., Shah D.D., Christner S.M. et al. Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. Br J Clin Pharmacol 2009;68(3):370—4.Egorin M.J., Shah D.D., Christner S.M. et al. Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. Br J Clin Pharmacol 2009;68(3):370—4.61. Quinta’s-Cardama A., Han X., Kantarjian H., Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 2009;114(2):261—3.Quinta’s-Cardama A., Han X., Kantarjian H., Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 2009;114(2):261—3.62. Hochhaus A., Giles F.J., Baccarani P. et al. Safety and efficacy of Nilotinib dose escalation 600 mg BID in patients with imatinib-resistant or intolerant chronic myeloid leukemia in chronic phase, accelerated phase or blast crisis. Blood 2007;110(11):1038.Hochhaus A., Giles F.J., Baccarani P. et al. Safety and efficacy of Nilotinib dose escalation 600 mg BID in patients with imatinib-resistant or intolerant chronic myeloid leukemia in chronic phase, accelerated phase or blast crisis. Blood 2007;110(11):1038.63. Biswas S.K., Zhao Y., Sandirasegarane L. Imatinib induces apoptosis by inhibiting PDGF- but not insulin-induced PI 3-kinase/Akt survival signaling in RGC-5 retinal ganglion cells. Mol Vis 2009;15:1599—610.Biswas S.K., Zhao Y., Sandirasegarane L. Imatinib induces apoptosis by inhibiting PDGF- but not insulin-induced PI 3-kinase/Akt survival signaling in RGC-5 retinal ganglion cells. Mol Vis 2009;15:1599—610.64. Matsuo E., Miyazaki Y. et al. Imatinib provides durable molecular and cytogenetic responses in a practical setting for both newly diagnosed and previously treated chronic myelogenous leukemia: a study in nagasaki prefecture, Japan. Int J Hematol 2007;85(2):132—9.Matsuo E., Miyazaki Y. et al. Imatinib provides durable molecular and cytogenetic responses in a practical setting for both newly diagnosed and previously treated chronic myelogenous leukemia: a study in nagasaki prefecture, Japan. Int J Hematol 2007;85(2):132—9.65. Hensley M.L., Ford J.M. Imatinib treatment: specific issues related to safety, fertility and pregnancy. Sem In Hematol 2003;40(2 suppl 2):21—5.Hensley M.L., Ford J.M. Imatinib treatment: specific issues related to safety, fertility and pregnancy. Sem In Hematol 2003;40(2 suppl 2):21—5.66. Kantarjian H., Talpaz M. et al. High-dose imatinib mesylate therapy in newly diagnosed philadelphia chromosome positive chronic myeloid leukemia. Blood 2004;103(8):2873—8.Kantarjian H., Talpaz M. et al. High-dose imatinib mesylate therapy in newly diagnosed philadelphia chromosome positive chronic myeloid leukemia. Blood 2004;103(8):2873—8.67. Bhargav R., Mahapatra M., Mishra P., Kumar R. Overdose with 6400 mg of imatinib: is it safe? Ann Oncol 2007;18(10):1750—1.Bhargav R., Mahapatra M., Mishra P., Kumar R. Overdose with 6400 mg of imatinib: is it safe? Ann Oncol 2007;18(10):1750—1.68. Gambacorti-Passerini K. et al. Gynecomastia in men with chronic myeloi leukemia after imatinib. Lancet 2003;361:1954—6.Gambacorti-Passerini K. et al. Gynecomastia in men with chronic myeloi leukemia after imatinib. Lancet 2003;361:1954—6.69. Cerchione C., Fabbricini R., Pane F. et al. Vitiligo-like lesions in an adult patient treated with Imatinib mesylate. Leuk Res 2009;33(8):104—5.Cerchione C., Fabbricini R., Pane F. et al. Vitiligo-like lesions in an adult patient treated with Imatinib mesylate. Leuk Res 2009;33(8):104—5.70. Oztas P., Erbasi S. Imatinib-induced erythrodermia in a patient with chronic myeloid leukemia. Acta Derm Venereol 2006;86(2):174—5.Oztas P., Erbasi S. Imatinib-induced erythrodermia in a patient with chronic myeloid leukemia. Acta Derm Venereol 2006;86(2):174—5.71. Woo S.M., Huh C.H. Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib. J Dermatol 2007;34(10):724—6.Woo S.M., Huh C.H. Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib. J Dermatol 2007;34(10):724—6.72. De Arriba J., Nerin C., Garcia E. et al. Severe hemolytic anemia and skin reaction in a patient treated with imatinib. Ann Oncol 2003;14:962.De Arriba J., Nerin C., Garcia E. et al. Severe hemolytic anemia and skin reaction in a patient treated with imatinib. Ann Oncol 2003;14:962.73. Novaretti M., Fonseca G., Conchon M. et al. First case of immunemediated haemolytic anaemia associated to imatinib mesylate. Eur J Haematol 2003;71:455—8.Novaretti M., Fonseca G., Conchon M. et al. First case of immunemediated haemolytic anaemia associated to imatinib mesylate. Eur J Haematol 2003;71:455—8.74. Cortes J. et al. Efficacy of nilotinib (AMN 107) in patients with newly diagnosed, previously untreated Philadelphia chromosome positive chronic myelogelous leukemia in early chronic phase. Blood 2007;110(11):abstr 29.Cortes J. et al. Efficacy of nilotinib (AMN 107) in patients with newly diagnosed, previously untreated Philadelphia chromosome positive chronic myelogelous leukemia in early chronic phase. Blood 2007;110(11):abstr 29.75. Talpaz M., Shah N.P., Kantarjian H. et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354(24):2531—41.Talpaz M., Shah N.P., Kantarjian H. et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354(24):2531—41.76. Kantarjian H.M. et al. Nilotinib is highly active and safe in chronic phase chronic myelogenous leukemia (CMLCP) patients with imatinib-resistance or in tolerance. Blood 2007;110:226: abstr 735.Kantarjian H.M. et al. Nilotinib is highly active and safe in chronic phase chronic myelogenous leukemia (CMLCP) patients with imatinib-resistance or in tolerance. Blood 2007;110:226: abstr 735.77. Le Coutre P. et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosomepositive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110(10):3540—6.Le Coutre P. et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosomepositive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110(10):3540—6.78. Nicolini F. et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosomepositive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110:870.Nicolini F. et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosomepositive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110:870.79. Nicolini E.F. et al. Expanding Nilotinib access in clinical trials (ENACT) study in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis, accelerated phase or chronic phase: preliminary safety analysis. ASCO Annual Meeting 2008: abstr 7059.Nicolini E.F. et al. Expanding Nilotinib access in clinical trials (ENACT) study in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis, accelerated phase or chronic phase: preliminary safety analysis. ASCO Annual Meeting 2008: abstr 7059.80. Cortes J. et al. Nilotinib is associated with minimal cross intolerance in patients with imatinib-intolerant Philadelphia-Positive chronic myelogenous leukemia in either chronic phase or accelerated phase. Blood 2007;110. Abstr 1040.Cortes J. et al. Nilotinib is associated with minimal cross intolerance in patients with imatinib-intolerant Philadelphia-Positive chronic myelogenous leukemia in either chronic phase or accelerated phase. Blood 2007;110. Abstr 1040.81. Jabbour E. et al. Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib intolerance chronic myeloid leukemia in chronic phase or accelerated phase. Blood 2008;112(11):abstr 3215.Jabbour E. et al. Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib intolerance chronic myeloid leukemia in chronic phase or accelerated phase. Blood 2008;112(11):abstr 3215.82. Nicolini E.F. et al. Expanding Nilotinib access in clinical trials (ENACT) study in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia: subgroup analysis of patients who failed prior dasatinib therapy. Hematologica 2009;94(2): abstr 633.Nicolini E.F. et al. Expanding Nilotinib access in clinical trials (ENACT) study in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia: subgroup analysis of patients who failed prior dasatinib therapy. Hematologica 2009;94(2): abstr 633.83. Stephens J. et al. Haematologica 2007;92(1):abstr 0552.Stephens J. et al. Haematologica 2007;92(1):abstr 0552.84. Stephens J. et al. Haematologica 2007;92(1):abstr 0658.Stephens J. et al. Haematologica 2007;92(1):abstr 0658.85. Cortes J. et al. Efficacy of dasatinib in patients with previously untreated chronic myelogelous leukemia in early chronic phase. Blood 2007;110(11):abstr 30.Cortes J. et al. Efficacy of dasatinib in patients with previously untreated chronic myelogelous leukemia in early chronic phase. Blood 2007;110(11):abstr 30.86. Shah N.P. et al. Intermittent target inhibition with dasatinib 100mg once daily preserves efficacy and improves tolerabiliry in imatinib-resistant and intolerant chronic phase chronic myeloid leukemia. J Clin Oncol 2008;26(19):1—9Shah N.P. et al. Intermittent target inhibition with dasatinib 100mg once daily preserves efficacy and improves tolerabiliry in imatinib-resistant and intolerant chronic phase chronic myeloid leukemia. J Clin Oncol 2008;26(19):1—987. Jayson G.C. et al. Blockade of platelet derived growth factor receptor-beta by CD860, humanized, PEGylated di-Fab', leads to fluid accu,ulation and its association with increased tumor vascularized volume. J Clin Oncol 2005;23:973—81.Jayson G.C. et al. Blockade of platelet derived growth factor receptor-beta by CD860, humanized, PEGylated di-Fab', leads to fluid accu,ulation and its association with increased tumor vascularized volume. J Clin Oncol 2005;23:973—81.88. Punnialingam S., Lavallade H., Bua M. et al. Pleural effusions in patients with chronic myeloid leukemia treated with dasatinib may have an immunemediated pathogenesis. Br J Haematol 2008;141:7345—47.Punnialingam S., Lavallade H., Bua M. et al. Pleural effusions in patients with chronic myeloid leukemia treated with dasatinib may have an immunemediated pathogenesis. Br J Haematol 2008;141:7345—47.89. Kneidinger M. et al. The effects of dasatinib on IgE receptor dependent activation and histamine release in human basophils. Blood 2008;111:3097—107.Kneidinger M. et al. The effects of dasatinib on IgE receptor dependent activation and histamine release in human basophils. Blood 2008;111:3097—107.90. Weichsel R. et al. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res 2008;14(8):2484—91.Weichsel R. et al. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res 2008;14(8):2484—91.91. Torres H.A. et al. Viral infection or reactication in patients during treatment with dasatinib. Leuk Lymph 2007;48(12):2308—9.Torres H.A. et al. Viral infection or reactication in patients during treatment with dasatinib. Leuk Lymph 2007;48(12):2308—9.92. Garcia-Munoz R. et al. Pavovirus B19 acute infection and reactivation of cytomegalovirus and herpes virus 6 in a chronic myeloid leukemia patient during treatment with dasatinib. Leukem Lymph 2007;48:2461—4.Garcia-Munoz R. et al. Pavovirus B19 acute infection and reactivation of cytomegalovirus and herpes virus 6 in a chronic myeloid leukemia patient during treatment with dasatinib. Leukem Lymph 2007;48:2461—4.93. State and role of Src family kinases in replication of herpes simplex virus 1. J Virol 2006;80:3349—59.State and role of Src family kinases in replication of herpes simplex virus 1. J Virol 2006;80:3349—59.94. Quintas-Cardama A. et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25(25):3908—13.Quintas-Cardama A. et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25(25):3908—13.95. Nicaise C. et al. Dasatinib pharmacokinetics and exposure-response: relationships to efficacy and safety in patients with chronic myelogenous leukemia in chronic phase. Hematologica 2008;93(1): abstr 0559.Nicaise C. et al. Dasatinib pharmacokinetics and exposure-response: relationships to efficacy and safety in patients with chronic myelogenous leukemia in chronic phase. Hematologica 2008;93(1): abstr 0559.96. Bargeon A. et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia. Am J Respirat Critic Care Med 2007;176:814—8.Bargeon A. et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia. Am J Respirat Critic Care Med 2007;176:814—8.97. Quintas-Cardama A. et.al. Association of pleural effusion and bleeding in patients with chronic myelogenous leukemia receiving dasatinib. ASH 2008;abstr 2112.Quintas-Cardama A. et.al. Association of pleural effusion and bleeding in patients with chronic myelogenous leukemia receiving dasatinib. ASH 2008;abstr 2112.98. Hochhaus A. et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008; 1—7.Hochhaus A. et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008; 1—7.99. Quintas-Cardama A. et al. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer 2009;115(11): 2482—90.Quintas-Cardama A. et al. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer 2009;115(11): 2482—90.100. Rizzo J.D. et al. Use of epoetin and darbopoetin in patients with cancer: 2007 American society of hematology/American society of clinical oncology clinical practice guideline update. Blood 2008;111:25—41.Rizzo J.D. et al. Use of epoetin and darbopoetin in patients with cancer: 2007 American society of hematology/American society of clinical oncology clinical practice guideline update. Blood 2008;111:25—41.101. Pye S.M. et al. The effects of imatinib on pregnancy outcome. Blood 2008;111(12):5505—8.Pye S.M. et al. The effects of imatinib on pregnancy outcome. Blood 2008;111(12):5505—8.102. Gschwing H.P. et al. Drug metab dispos 2008;33(10):1902—12.Gschwing H.P. et al. Drug metab dispos 2008;33(10):1902—12.103. Rousselot P. et al. Imatinib mesylate discontinuation inpatients with chronic myeloid leukemia in complete molecular remission for more than 2 years. Blood 2007;109:58—60.Rousselot P. et al. Imatinib mesylate discontinuation inpatients with chronic myeloid leukemia in complete molecular remission for more than 2 years. Blood 2007;109:58—60.104. Russel M.A. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk. J Perinatol 2007;27:241—3.Russel M.A. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk. J Perinatol 2007;27:241—3.105. Hansley M.L. et al. Imatinib treatment: specific issues related to safety, fertility and pregnancy. Sem Hematol 2003;40:21—5.Hansley M.L. et al. Imatinib treatment: specific issues related to safety, fertility and pregnancy. Sem Hematol 2003;40:21—5.106. Gambacorti-Passerini C. et al. Gynecomastia in men with chronic myeloid leukemia after imatinib. Lancet 2003;363:1954—6.Gambacorti-Passerini C. et al. Gynecomastia in men with chronic myeloid leukemia after imatinib. Lancet 2003;363:1954—6.107. Ramasamy K. et al. Successful pregnancies involving men with chronic myeloid leukemia on imatinib therapy. Br J Haematol 2007;137:374—5.Ramasamy K. et al. Successful pregnancies involving men with chronic myeloid leukemia on imatinib therapy. Br J Haematol 2007;137:374—5.108. Ault P. et al. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol 2006;24:1204—8.Ault P. et al. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol 2006;24:1204—8.109. Breccia M. et al. Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: report of five cases. Leuk Res 2008;32:519—20.Breccia M. et al. Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: report of five cases. Leuk Res 2008;32:519—20.110. Sette C. et al. The role of stem cell factor and of alternative c-KIT gene products in the establishment, maintenance and function of germ cells. Int J Dev Biol 2002;44:599—608Sette C. et al. The role of stem cell factor and of alternative c-KIT gene products in the establishment, maintenance and function of germ cells. Int J Dev Biol 2002;44:599—608111. Basciani S. et al. Expression of PDGF-A, PDGF-B and PDGFR-alpha and PDGFR-beta during human testicular development and disease. J Clin Endocrinol Metab 2002;87: 2310—9.Basciani S. et al. Expression of PDGF-A, PDGF-B and PDGFR-alpha and PDGFR-beta during human testicular development and disease. J Clin Endocrinol Metab 2002;87: 2310—9.112. Jabbour E., Hochaus A., Cortes J. et al. Choosing the best treatment strategy for chronic myeloid leukemia patients, resistant to imatinib: weighing the efficacy and safety of individual drugs with BCRABL murtations and patient history. Leukemia 2009; Oct 1 [Epub ahead of print].Jabbour E., Hochaus A., Cortes J. et al. Choosing the best treatment strategy for chronic myeloid leukemia patients, resistant to imatinib: weighing the efficacy and safety of individual drugs with BCRABL murtations and patient history. Leukemia 2009; Oct 1 [Epub ahead of print].